Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 22 articles:
HTML format



Single Articles


    May 2024
  1. TENG Z, Xu S, Lei Q
    [Retracted] Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB?152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Oncol Rep. 2024;51:66.
    PubMed     Abstract available


    December 2023
  2. LI J, Tang B, Miao Y, Li G, et al
    Targeting of STAT5 using the small molecule topotecan hydrochloride suppresses acute myeloid leukemia progression.
    Oncol Rep. 2023;50:208.
    PubMed     Abstract available


    August 2023
  3. WANG X, Rong S, Sun Y, Yin B, et al
    NDRG3 regulates imatinib resistance by promoting beta‑catenin accumulation in the nucleus in chronic myelogenous leukemia.
    Oncol Rep. 2023;50:152.
    PubMed     Abstract available


    May 2023
  4. LIU YH, Zhu M, Lei PP, Pan XY, et al
    [Corrigendum] ND‑09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR‑ABL signaling.
    Oncol Rep. 2023;49:81.
    PubMed     Abstract available


    February 2023
  5. LIANG X, Xia R
    [Corrigendum] Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia.
    Oncol Rep. 2023;49:26.
    PubMed     Abstract available


    December 2022
  6. LEONCINI PP, Vitullo P, Reddel S, Tocco V, et al
    MicroRNA profiling of paediatric AML with FLT-ITD or MLL-rearrangements: Expression signatures and in vitro modulation of miR-221-3p and miR-222-3p with BRD4/HATs inhibitors.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


    August 2022
  7. KAEHLER M, Litterst M, Kolarova J, Bohm R, et al
    Genomewide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitorresistant CML cells.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


    June 2022
  8. LALIC H, Aurer I, Batinic D, Visnjic D, et al
    Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    May 2022
  9. FORGIONE MO, McClure BJ, Page EC, Yeung DT, et al
    TP53 lossoffunction mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    April 2022
  10. LI Z, Zhang J, Zhou M, Li JL, et al
    Epigenetic therapy with chidamide alone or combined with 5azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    February 2022
  11. HUANG FL, Yu SJ, Liao EC, Li LY, et al
    Niclosamide suppresses Tcell acute lymphoblastic leukemia growth through activation of apoptosis and autophagy.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    January 2022
  12. LIANG X, Xia R
    Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    October 2021
  13. AYE KT, Wattanapongpitak S, Supawat B, Kothan S, et al
    Gallic acid enhances pirarubicininduced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and Pglycoprotein inhibition.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    July 2021
  14. YAO J, Luo Y, Zeng C, He H, et al
    UHRF1 regulates the transcriptional repressor HBP1 through MIF in T acute lymphoblastic leukemia.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  15. SHI YF, Huang ZY, Huang YS, Dong RJ, et al
    Interaction between CD9 and PI3Kp85 activates the PI3K/AKT signaling pathway in Blineage acute lymphoblastic leukemia.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  16. LIU YH, Zhu M, Lei PP, Pan XY, et al
    ND09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCRABL signaling.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  17. FU JF, Shih LY, Yen TH
    HOXA11 plays critical roles in disease progression and response to cytarabine in AML.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    June 2021
  18. DONG L, Xu WW, Li H, Bi KH, et al
    [Retracted] In vitro and in vivo anticancer effects of marmesin in U937 human leukemia cells are mediated via mitochondrialmediated apoptosis, cell cycle arrest, and inhibition of cancer cell migration.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  19. GENG Y, Wu W, Zhou L, Li J, et al
    Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


    March 2021
  20. JING W, Zhou M, Chen R, Ye X, et al
    In vitro and ex vivo anti‑tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2‑overexpressing leukemia cells.
    Oncol Rep. 2021;45:1142-1152.
    PubMed     Abstract available


    February 2021
  21. ZHANG P, Wang Y, Qin M, Li D, et al
    Involvement of Blnk and Foxo1 in tumor suppression in BCRABL1transformed proB cells.
    Oncol Rep. 2021;45:693-705.
    PubMed     Abstract available


    January 2021
  22. GONG Y, Deng J, Wu X
    Germline mutations and blood malignancy (Review).
    Oncol Rep. 2021;45:49-57.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.